This study is in progress, not accepting new patients
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
Breast Neoplasms breast cancer postmenopausal women estrogen-receptor positive HER2 negative locoregionally recurrent metastatic Palbociclib (PD-0332991) PALOMA-2 Letrozole Palbociclib PD-0332991 + Letrozole
Lead Scientist at UCSF
- Hope Rugo
Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.
- in progress, not accepting new patients
- Start Date
- Completion Date
- To obtain contact information for a study center near you, click here.
- Phase 3
- Study Type
- Last Updated